Condition: Non Small Cell Lung Cancer Metastatic · Sponsor: Memorial Sloan Kettering Cancer Center
The researchers are doing this study is to find out whether treating brain metastasis with SRS after 3 months of therapy with osimertinib is better than treating with osimertinib alone in people with NSCLC. The researchers will also look at how the study intervention impacts participants' quality of life. The researchers will measure quality of life by having participants complete questionnaires.
This description comes directly from the study's public registry record.
Luke Pike, MD · 212-639-8157 · pikel@mskcc.org
Helena Yu, MD · 646-608-3912
Always discuss trial participation with your own doctor first.
| BAPTIST ALLIANCE - MCI (Data Collection Only) | Miami, Florida, United States | Recruiting |
| Memorial Sloan Kettering Basking Ridge (All Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (All Protocol Activities) | Rockville Centre, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06741085